NCT06613399Not yet recruiting
Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer.
A Randomized Controlled Study of Multi-technology Integration Total Mesorectal Excision (MTI-TME) Versus Conventional Total Mesorectal Excision (C-TME) for the Treatment of Middle and Distal Rectal Cancer.
Source: ClinicalTrials.gov · Last updated 26 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A multicenter, prospective, randomized, controlled clinical trial of multi-technology integration total mesorectal excision (MTI-TME) versus conventional total mesorectal excision (C-TME) for the treatment of middle and distal rectal cancer
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 324 (estimated)
- First submitted
- 19 Sept 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Colorectal cancer
- NCT number
- NCT06613399
What you commit to
- Study type: Interventional
- Planned participants: 324
- From 1 Jan 2025 to the primary completion date, 1 Jan 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ineligible for laparoscopic surgery;
Other illness
- Developing other malignant tumors within 5 years;
- Patients with severe mental disorders;
- Severe intestinal diseases;
- Poor general condition and uncontrolled comorbidities;
Other
- Multiple primary colorectal tumors;
- Pregnant or lactating women;
- Participating in other clinical trials.
Who the study is looking for
- Participants must be aged 18 to 75.
- Histopathological examination of the preoperative biopsy confirms adenocarcinoma.
- Preoperative MRI shows the tumor\'s lower margin is below the umbilical ligament.
- High-resolution CT and MRI do not indicate suspicious distant metastasis.
- Participants\' general condition is acceptable, with an ASA score of ≤3 before surgery.
- Participants must sign an informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.